ABSTRACT Thymic function was evaluated by quantitation of circulating thymic factor in patients with several forms of severe infantile immunodeficiency diseases. Direct quantitation of thymic factor in serum of patients with severe combined immunodeficiency revealed heterogeneity of this syndrome by this parameter, as was also shown by study of susceptibility of the marrow cells to differentiation in vitro. Thymic factor was not detectable in one patient with severe combined immunodeficiency, but was present in normal or near-normal concentrations in three others. Circulating levels of this hormonal activity were also not detectable in a patient with DiGeorge athymic syndrome. Following marrow or fetal liver transplantation, which corrected the severe combined immunodeficiency, thymic factor levels either increased slightly or did not change appreciably. Fetal thymic transplantation, which together with fetal liver transplantation corrected the immunodeficiency in one patient with severe combined immunodeficiency, was associated with increase of thymic factor to normal levels. Fetal thymus transplantation alone, which was employed to correct the immunodeficiency of DiGeorge athymic syndrome, caused an increase in thymic factor activity to normal or near normal levels in this patient.
Presence of a functional thymus in children with severe combined immunodeficiency (SCID) has not been extensively investigated. The defect in humoral and cell-mediated immunity in these patients has been attributed to either a lack or an abnormality of lymphoid stem cells in their marrow. Normal human marrow cells can be differentiated in vitro into cells bearing thymus-derived (T)-lymphocyte characteristics by thymic extracts or purified peptides (1) (2) (3) . In contrast, narrow cells from patients with variants of SCID are either refractory to such differentiative influences or capable of only partial differentiation, limited to appearance of human T-lymphocyte antigenicity (HTLA) marker (4) . Prior studies have not, however, permitted evaluation of the thymic function in vivo in this apparently heterogenous group of patients. Lack of full differentiation to normal T-cell function, which is sometimes observed following transplantation of stem cells from bone marrow or fetal liver to correct the immunodeficiency, might reflect the absence of a normally functioning thymus (5) . It is especially important, then, to study thymic function in patients with these diseases, because the thymus is often small and poorly developed, and the small thymus shows considerable morphologic heterogeneity (6) .
We have now extended our studies of patients with various forms of immunodeficiency, using direct determination of 
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circulating thymic factor (TF) in serum (7) . This parameter was investigated in five patients with SCID and one with thymic hypoplasia or DiGeorge syndrome. Serum TF was measured at different times before and after bone marrow, fetal liver, fetal liver plus thymus transplantation, or thymus transplantation only. The direct analysis of serum TF activity could provide yet another means to evaluate the presence of a functional thymus before transplantation. In certain patients with immunodeficiency, either SCID or DiGeorge syndrome, recognition of a functional thymic deficiency could establish a need for transplantation of a thymus either alone or along with fetal hematopoietic stem cells. Further, measurement of serum TF activity after thymic transplantation should permit evaluation of the influence of the thymus graft.
MATERIAL AND METHODS Marrow Cell Differentiation. Differentiation studies on human marrow precursor cells were performed in vitro by the procedure of Incefy et al. (3, 8) . After incubation with human or bovine thymic extracts (9) and purified thymic peptides (10, 11) , appearance of T-lymphocyte characteristics on precursor cells was detected by two T-cell surface markers: human Tlymphocyte antigenicity (HTLA phenotypes) (2) recognized by an anti-human T-cell serum in a microcytotoxicity test, and receptors for sheep erythrocytes as detected by the spontaneous E-rosette formation technique with sheep erythrocytes (3).
TF Evaluation. Rosette-forming cells from the spleen of thymectomized mice are less sensitive to azathioprine than are those from normal mice (70 ,tg/ml required for rosette inhibition instead of 1 ,ug/ml). Thymic extracts or human and animal sera with TF activity restore normal sensitivity to azathioprine of rosette-forming cells from adult thymectomized mice after a short incubation at 37°. This change is the basis for the biological assay used for evaluation of serum TF activity.
The assay procedure and the mode of preparation of sera for this evaluation have been described in detail by Dardenne and Bach (12) . Sera (4, 8, 14) . The presence or absence of circulating serum thymic factor activities is also indicated in relation to these investigations. bone-marrow-derived (B) lymphocytes with immunoglobulins at their surface but lacked T-lymphocytes, had marrow cells that could be induced to bear only HTLA+ phenotypes but not sheep erythrocyte receptors (4) . After the initial fetal liver plus thymus transplantation, which failed to produce either chimerism or functional immunity, marrow cells from patient K.M. could be induced to develop both T-cell markers. Immunologic reconstitution with sustained chimerism developed following engraftment of a second fetal liver. The latter patient (M.W.), who did not possess detectable levels of TF in his serum before transplant or after two fetal liver grafts, developed almost normal levels of this hormone after having been given a thymus transplant and another fetal liver. This child showed clinical and laboratory evidence of successful reconstitution, but the bone marrow abnormality was not corrected. Marrow cells from another patient (J.J.) were studied for susceptibility to inducers of differentiation only following fetal liver transplantation and showed a weak response. J.J.'s serum TF level was low on three occasions, but activity was not completely absent. Patient O.T., with DiGeorge syndrome, had cells in his marrow that could be induced to differentiate to cells with T-cell markers both before and after fetal thymus transplantation given to correct his immunodeficiency. No serum TF could be detected prior to a thymus graft; however, this hormone was detectable one day following the graft and has been present in the same or greater concentrations ever since. TF levels in severe combined immunodeficiency diseases Fig. 1 shows three different patterns of circulating serum TF activity in patients with SCID. Patients M.R. and S.C. had normal or near normal levels of TF before bone marrow transplantation and normal levels of TF following marrow transplantation. Similarly, patient K.M. had near normal levels before transplantation and reached normal levels following fetal liver plus thymus transplantation. In contrast, patient M.W. lacked serum TF activity before transplantation and did not exhibit TF activity in his serum after two fetal liver transplants, the second of which established a chimeric state. This patient, however, acquired normal levels of TF after he was given a fetal thymus transplant which, with the fetal liver transplants, corrected his SCID.
TF levels in DiGeorge syndrome Proc. Natl. Acad. -Sci. USA 74 (1977) I-L culating TF before fetal thymus transplantation and levels increasing to normal after reconstitution are clearly apparent.
DISCUSSION
Our investigations and those of others indicate that the term severe combined immunodeficiency encompasses a heterogenous group of disorders. In our prior studies, we showed heterogeneity in the response of-marrow of patients with this syndrome tjs d vis susceptibility of marrow cells to differentiation (4, 8, 14) . In one group we found that marrow cells which can respond to induction with thymic extracts or thymic peptides were apparently lacking, and in the other group, in which some B-cell development was evident, we found the marrow cells could be induced to form certain markers but not others (4) .
In the present study, by applying a new method for assay of circulating TF (7, 12, 15) , we have also obtained additional evidence of heterogeneity in patients with SCID. Three different patterns were observed. One patient (M.R.) had nearly normal amounts of TF, which did not change significantly following immunologic reconstitution with marrow cells from a non-related donor matched at the HLA-B and -D loci. Two other patients (S.C. and K.M.) had somewhat lower levels of TF, which reached normal range in one instance following successful immunologic reconstitution with marrow from a histocompatible sibling donor. The other reached normal range following correction by fetal liver plus thymus transplantation. The third form, in patient M.W., showed the TF to be undetectable before and after engraftment of fetal liver cells. Immunologic reconstitution and establishment of normal TF levels occurred only after transplantation of a fetal thymus followed by engraftment of a second fetal liver.
In the patient with thymic hypoplasia, syndrome of DiGeorge, TF was undetectable, as might have been expected. Following thymic transplantation to correct the immunologic function, TF became detectable 1 day after transplantation and achieved levels slightly lower than normal thereafter. These studies show clear influence of thymic transplantation to correct deficiencies of TF levels. The findings in patient S.C. suggest also that bone marrow transplantation can influence thymic function as assayed in this way. Such an influence could be due to trophic effect of T-cell precursors on thymic development and function, a possible influence that needs further study.
This method of analysis of SCID may well be clinically useful in defining patients with SCID whose thymic function is so defective as to necessitate transplantation of a thymus along with fetal hematopoietic precursors. Coupled with our previously reported assessment of precursor cell abnormalities or potentialities using induction of marrow cell differentiation, variants of SCID potentially correctable by engraftment of a fully differentiated, lymphocyte-depleted thymus might be delineated by this technique (16) . These findings establish the clinical validity of the assay used, because the studies carried out in blindfold fashion readily detected the thymic deficiency in a patient with DiGeorge syndrome and revealed the thymic influence reflected in clinical evidence of immunologic reconstitution following thymic transplantation. 
